LACTATE DEHYDROGENASE AS A BIOMARKER FOR COVID-19

Dr. Pankaj Chauhan; Dr. Divya Thakur; Vidushi Jindal; Ayushi Singla; Dr. Vikas Jindal; Dr. Amit Goel; Dr. Poonam Rajput; Dr. ShubhKarmanjit Singh Bawa

Volume : IX, Issue : VI, June - 2020

LACTATE DEHYDROGENASE AS A BIOMARKER FOR COVID-19

Dr. Pankaj Chauhan, Dr. Divya Thakur, Vidushi Jindal, Ayushi Singla, Dr. Vikas Jindal, Dr. Amit Goel, Dr. Poonam Rajput, Dr. Shubhkarmanjit Singh Bawa

Abstract :

Coronavirus disease 2019 (COVID-19) has infected more than 4 million people within 4 months. There is an urgent need to properly identify high-risk cases that are more likely to deteriorate even if they present mild diseases on admission. Despite the fact that COVID-19 patients have mild symptoms and signs in their early stage, about 8–30% of patients would eventually develop severe illness. The 28-day mortality rate of critically ill patients is over 60%. It has been decided as a completely unique enveloped RNA Betacoronavirus-2 that has currently been decided as severe acute respiratory syndrome Coronavirus -2 (SARS-CoV-2) causing a disorder referred to as Coronavirus illness 2019 (COVID-19). In light of these uncertainties, we summarize the specific biomarkers like Lactate dehydrogenase (LDH) to assess if they may be able to expect medical effects and correlate with the severity of COVID-19 sickness. This review will improve our understanding of the correlation between COVID‐19 and LDH to enhance our diagnostic measures in the future.